|
Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. |
|
|
|
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Medivation/Pfizer; Pfizer |
Speakers' Bureau - Clinical Care Options; Med Learning Group; Medpage; Medscape; Physicans' Education Resource; Prime Oncology; UpToDate |
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Genentech (Inst); pfizer (Inst); Zenith Epigenetics (Inst) |
Patents, Royalties, Other Intellectual Property - UptoDate |
Travel, Accommodations, Expenses - Clinical Care Options; Med Learning Group; Medscape; Physicans' Education Resource |
Other Relationship - Medivation/Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Biotheranostics; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Seagen |
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Genentech; Genomic Health; Immunomedics; Novartis; Puma Biotechnology; Seagen |
|
|
Honoraria - Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Genomic Health; Immunomedics; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Research to Practice |
Consulting or Advisory Role - Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Genomic Health; Immunomedics; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Research to Practice |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Immunomedics; Novartis; Pfizer; Seagen |
|
|
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech; Immunomedics; Merck; Novartis; Pfizer |
Research Funding - Eisai; Genentech; Merck; Novartis; Pfizer; Puma Biotechnology |
Expert Testimony - Novartis |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Stock and Other Ownership Interests - Delphi Diagnostics; Eiger BioPharmaceuticals; ISIS Pharmaceuticals; Nuvera Biosciences |
Consulting or Advisory Role - Almac Diagnostics; Merck |
Patents, Royalties, Other Intellectual Property - Intellectual property; Intellectual Property (expired) |
Travel, Accommodations, Expenses - Luminex; Merck |
(OPTIONAL) Uncompensated Relationships - Delphi Diagnostics |
|
|
Consulting or Advisory Role - Abbvie; Aduro Biotech; Celgene; Daiichi Sankyo; G1 Therapeutics; Genentech/Roche; Immunomedics; Lilly; Merck; Natera; Pfizer |
Research Funding - Abbvie (Inst); Bayer (Inst); Biothera (Inst); Calithera Biosciences (Inst); EMD Serono (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst) |
Other Relationship - G1 Therapeutics; Pfizer (I) |